Evidence map›Paper›PMID 39524005›Full record

ReviewBiomolecules & biomedicine2025

Research progress on melatonin, 5-HT, and orexin in sleep disorders of children with autism spectrum disorder.

Wenjun Ding, Yiran Xu, Wencong Ding, Qiongyan Tang, Bohao Zhang, Yangyang Yuan, Jian Jin

Abstract readReview
In one paragraph

Review in Biomolecules & biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wenjun DingScientific research center, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yiran XuScientific research center, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wencong DingIntervention Neurosurgery Department, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Qiongyan TangNeurology Department, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Bohao ZhangScientific research center, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yangyang YuanScientific research center, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jian JinScientific research center, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sleep disorders are among the common comorbidities of autism spectrum disorder (ASD), which not only affect the daily life and learning ability of children but may also exacerbate other symptoms of ASD, seriously impacting the quality of life of children and their families. Given this, understanding the neurobiological mechanisms of sleep disorders in children with ASD has significant research value for developing effective intervention strategies. Melatonin, 5-hydroxytryptamine (5-HT), and orexin are key neurotransmitters that regulate the sleep-wake cycle. Through in-depth analysis of the biological functions and regulatory pathways of these neurotransmitters, new perspectives may be provided for personalized treatment of sleep disorders in children with ASD. This article reviews the research progress on melatonin, 5-HT, and orexin in sleep disorders among children with ASD, focusing on exploring the mechanisms of these key neurotransmitters in sleep disorders of children with ASD and how they affect the sleep-wake cycle, providing a theoretical basis for improving the sleep quality of children with ASD.

Indexed as

Autism Spectrum DisorderMelatoninOrexinsSerotoninSleep Wake DisordersChildHumansNeurotransmitter AgentsSleepMelatoninNeurotransmitter AgentsOrexinsSerotonin

Identifiers

PMID39524005
PMCPMC12010984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.